

Looking Closely at the Options for the Patient With Advanced ALK-Positive NSCLC CME

THURSDAY, 16 APRIL 2020

TIME: 18:00 – 19:00

VENUE: PALEXPO, GENEVA, SWITZERLAND | ROOM A

A Medscape **LIVE!** EVENT

MODERATOR



Sanjay Popat, PhD, FRCP
Consultant Medical Oncologist
Royal Marsden Hospital
Professor of Thoracic Oncology
The Institute of Cancer Research
London, United Kingdom

PANELISTS



Ross Camidge, MD, PhD
Director of Thoracic Oncology
University of Colorado
Aurora, Colorado, United States



Rosario García Campelo, MD
Medical Oncology Unit
Head of Clinical Research Unit
University Hospital A Coruña
INIBIC
A Coruña, Spain

AGENDA

18:00

***With More Options Come More Questions:
Challenges for the Patient With De Novo
ALK-Positive Metastatic NSCLC***
Sanjay Popat, PhD, FRCP

***Debating the First-Line Treatment
Options for the Patient With ALK-Positive
Metastatic NSCLC***

Sanjay Popat, PhD, FRCP

18:10

***What Do the Latest Clinical Trial Data
Show Regarding the Efficacy and Safety
of ALK Inhibitors in the First Line?***

Ross Camidge, MD, PhD
and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

***Should the Site of Metastasis Influence
our Choice?***

Ross Camidge, MD, PhD
and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:25

***What About Quality of Life and Other
Patient Factors?***

Ross Camidge, MD, PhD
and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

***Anticipating, Monitoring, and Managing
Adverse Events***

Ross Camidge, MD, PhD
and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:35

So Which ALK Inhibitor for Which Patient?

Ross Camidge, MD, PhD and Rosario
García Campelo, MD Moderated
by Sanjay Popat, PhD, FRCP

***What Does This Mean for Second-Line
Treatment?***

Ross Camidge, MD, PhD
and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:50

Addressing Your Questions
Faculty Panel

19:00

Concluding Remarks and Close
Sanjay Popat, PhD, FRCP